Intercept Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ICPT research report →
Companywww.interceptpharma.com
Intercept Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults.
- CEO
- Jerome B. Durso
- IPO
- 2012
- Employees
- 341
- HQ
- New York City, NY, US
Price Chart
Valuation
- Market Cap
- $794.69M
- P/E
- 5.58
- P/S
- 2.78
- P/B
- 6.90
- EV/EBITDA
- -17.45
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 99.66%
- Op Margin
- -23.88%
- Net Margin
- 40.31%
- ROE
- -253.45%
- ROIC
- 10.37%
Growth & Income
- Revenue
- $285.71M · -21.39%
- Net Income
- $115.17M · 179.42%
- EPS
- $3.41 · 174.95%
- Op Income
- $-68,216,000
- FCF YoY
- 34.94%
Performance & Tape
- 52W High
- $21.86
- 52W Low
- $8.82
- 50D MA
- $15.66
- 200D MA
- $14.71
- Beta
- 0.88
- Avg Volume
- 2.05M
Get TickerSpark's AI analysis on ICPT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 8, 23 | AKKARAJU SRINIVAS | sell | 8,111 |
| Nov 8, 23 | AKKARAJU SRINIVAS | sell | 2,174 |
| Nov 8, 23 | AKKARAJU SRINIVAS | sell | 2,966 |
| Nov 8, 23 | AKKARAJU SRINIVAS | sell | 12,089 |
| Nov 8, 23 | AKKARAJU SRINIVAS | sell | 12,790 |
| Nov 8, 23 | AKKARAJU SRINIVAS | sell | 12,547 |
| Nov 8, 23 | AKKARAJU SRINIVAS | sell | 275 |
| Nov 8, 23 | AKKARAJU SRINIVAS | sell | 2,748 |
| Nov 8, 23 | AKKARAJU SRINIVAS | other | 640,688 |
| Nov 8, 23 | AKKARAJU SRINIVAS | sell | 1,750 |
Our ICPT Coverage
We haven't published any research on ICPT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ICPT Report →